MNKD Stock Summary and Trading Ideas (Mannkind | NASDAQ:MNKD)

MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.

Mannkind trades on the NASDAQ stock market under the symbol MNKD.

As of April 18, 2024, MNKD stock price declined to $4.08 with 1,212,163 million shares trading.

MNKD has a beta of 0.99, meaning it tends to be less sensitive to market movements. MNKD has a correlation of 0.05 to the broad based SPY ETF.

MNKD has a market cap of $1.08 billion. This is considered a Small Cap stock.

Last quarter Mannkind reported $58 million in Revenue and $.02 earnings per share. This beat revenue expectation by $5 million and exceeded earnings estimates by $.02.

In the last 3 years, MNKD stock traded as high as $5.75 and as low as $2.49.

The top ETF exchange traded funds that MNKD belongs to (by Net Assets): VTI, IWM, XBI, VXF, IBB.

MNKD has underperformed the market in the last year with a price return of -4.2% while the SPY ETF gained +22.3%. However, in the short term, MNKD had mixed performance relative to the market. It has outperformed in the last 3 months, returning +24.4% vs +6.1% return in SPY. But in the last 2 weeks, MNKD shares have been beat by the market, returning -7.9% compared to an SPY return of -3.8%.

MNKD support price is $3.97 and resistance is $4.23 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MNKD stock will trade within this expected range on the day.